The absorption, metabolism, and clearance of progesterone from the peripheral circulation were investigated in five postmenopausal women after oral admimistration of 100 mg daily for five consecutive days. Maximal plasma concentrations of progesterone were observed within four hours after ingestion of the last dose, when the range (22-11-34 18 nmol/l; 696-1077 ng/100 ml) was comparable with that observed during the mid-luteal phase of the ovarian cycle. The surge in values lasted six hours, and progesterone concentrations remained raised for at least 96 hours. Of the three metabolites studied, the plasma concentrations of pregnanediol-3a-glucuronide were most raised by treatment, the peak values ranging from 1097 nmol/l (549 stg/100 ml) to over 2000 nmol/l (100 ug/100 ml), which was the upper limit of the assay used. Concentrations of 17-hydroxyprogesterone were least raised, and the peak values ranged from 4-32 to 9 68 nmol/I (143-319 ng/100 ml).
Introduction
Synthetic progestogens have been used with benefit to manage dysfunctional uterine bleeding, endometrial hyperplasia and carcinoma, premenstrual tension, and endometriosis. In addition, they have been combined with oestrogens in oral contraceptive preparations and to treat menopausal symptoms. These synthetic steroids possess chemical configurations based on either 19 or 21 carbon atoms. The structural differences lead to variations in biological effects. Certain progestogens possess androgenic effects while others have antiandrogenic and some even oestrogenic properties. Adverse reactions owing to excessive androgenic or oestrogenic activity are well recognised. '-3 Naturally occurring progesterone has rarely been used in clinical practice. Doses of 1000 mg/day have been administered by mouth to pregnant women with a history of habitual abortion and low pregnanediol concentrations: in 60O' of pregnancies a viable baby was delivered.4 Doses of 300 mg daily inhibit ovulation.5 In men 100 mg produced a plasma surge lasting less than six hours.6 Until now, no information has been W P COLLINS, S CAMPBELL available on the pharmacodynamics of progesterone after oral administration in women.
We designed the present study to assess the rate of absorption of progesterone from the gastrointestinal tract and to determine the concentration appearing in the peripheral circulation. We studied the hormone's metabolism by determining its conversion to pregnanediol-3a-glucuronide, 20t-dihydroprogesterone, and 17-hydroxyprogesterone. Finally, we evaluated the importance of oral progesterone as a precursor of oestradiol.
Patients and methods
Five asymptomatic postmenopausal women volunteered to participate in the study. All were parous, had intact ovaries, and had experienced a natural menopause between two and eight years previously. Their ages ranged from 51 to 57 years and their weights from 61 5 to 92-4 kg. Four had never received any hormonal medication, but the fifth had been prescribed an oestrogen and progestogen preparation for 36 months to alleviate menopausal symptoms. This treatment had been stopped 12 months previously.
The study lasted 11 days. To obtain baseline values venepuncture was performed between 0900 and 1000 on days 1 and 2. For the next five consecutive days (days 3-7) one progesterone capsule containing 100 mg pure steroid was given by mouth at 0800.
On day 7 venepuncture was performed hourly from 0900 to 1600 and again at 2000. Additional blood samples were taken at 0800 on days 8, 9, 10, and 11-that is, 24, 48, 72, and 96 hours after the last capsule was administered. Each 20 ml blood sample was collected into lithium heparin tubes and centrifuged immediately, and the plasma stored at -20°C.
All concentrations of steroid hormones were measured by radioimmunoassay. The method for progesterone was that described by Youssefnejadian et al,7 except that we used a more specific antiserum to progesterone-l 1 x-succinyl-bovine thyroglobulin, which reduced the cross-reaction with 5x-dihydroprogesterone to less than 1500.
We measured 20oc-dihydroprogesterone and 17-hydroxyprogesterone concentrations by the methods of Florensa et al8 and Youssefnejadian et al9 respectively. The concentration of pregnanediol-3ac-glucuronide was measured in a 50 ,ul plasma aliquot by adapting the method for estimating the concentration in urine.10 Oestradiol was assayed by the method of Emment et al," except that we used a more specific antiserum to oestradiol-6-carboxymethyl oxime-BSA, which reduced the cross-reaction with oestrone to less than 200.
For each steroid we examined the distribution of values by calculating the arithmetic mean, geometric mean, median, degree of skewness, and kurtosis. The results obtained between 0900 and 1600 on day 7 were examined similarly after adjusting the time relative to the peak value for progesterone. As all values approximated to a normal distribution we compared the concentrations before and after ingestion of progesterone by using Student's t test.
Results Figure 1 shows the concentration of plasma progesterone in all samples from the five patients. All pretreatment concentrations (days 1 and 2) were within the postmenopausal range for our laboratory. Interpatient differences in absorption of progesterone are shown by the variation in the time taken to achieve maximal plasma concentrations after administration of the last capsule. Thus in three patients maximal concentrations occurred one hour after the last capsule had been taken. In the two other patients, however, absorption was slower and peak values were reached three hours later at 1200. Similar patterns were observed for pregnanediol-3a-glucuronide, 20x-dihydroprogesterone, and 17-hydroxyprogesterone.
To establish the temporal relation in plasma between concentrations of progesterone and those of pregnanediol-3x-glucuronide, 20cx-dihydroprogesterone, 1 7-hydroxyprogesterone, and oestradiol we standardised the values obtained between 0900 and 1600 on day 7 by using the maximal plasma concentration of progesterone as a reference point P. Figure 2 shows the means of the results, the baseline values on days 1 and 2, and the values obtained between 24 and 96 hours after the last capsule was taken. All pretreatment values were within the postmenopausal range for our laboratory.
The plasma concentrations of progesterone, pregnanediol-3ot-glucuronide, 20ac-dihydroprogesterone, and 17-hydroxyprogesterone reached a peak simultaneously. Progesterone concentrations fell most rapidly, and four hours after they were maximal approximated to concentrations of 20ao-dihydroprogesterone. Thereafter, the concentrations of these two hormones fell similarly, those of 20x-dihydroprogesterone just exceeding those of the parent compound. Concentrations of pregnanediol-3x-glucuronide on days 7-11 greatly exceeded those of 20a-dihydroprogesterone and 17-hydroxyprogesterone; those of 17- (table) . Concentrations of progesterone were significantly raised when maximal (p < 0-0005) and 96 hours after the end of treatment (p < 0-01).
Concentrations of pregnanediol-3ac-glucuronide and 20a-dihydroprogesterone were significantly raised when maximal and for up to 24 hours after the end of treatment (p < 0-0005). The concentration of 1 7-hydroxyprogesterone was significantly raised only when maximal (p <00025), and had returned to within the pretreatment range within 12 hours after the end of treatment. Oestradiol concentrations did not change significantly during the study. 
17-hydroxy-
progesterone, and oestradiol before and after oral administration of progesterone. The concentrations on day 7 were standardised by taking the peak plasma concentration of progesterone as the reference point P.
Conversion: SI to traditional units-Pregnanediol-3xe-glucuronide: 1 nmol/l 50 ng/l00 ml. Progesterone: 1 nmol/l132 ng/100 ml. 20x-Dihydroprogesterone: 1 nmolIl 32 ng/ 100 ml. 17-Hydroxyprogesterone: 1 nmol/l 33 ng/100 ml. Oestradiol: 1 pmol/l-27 pg/l00 ml.
Discussion
The mass of progesterone administered daily in this study (100 mg) is about four times the mean mass produced daily by the ovary during the mid-luteal phase of the ovarian cycle. 12 The peak progesterone concentrations, however, were within the range found in the luteal phase, indicating that about 250( of the progesterone taken by mouth appeared in peripheral plasma.
This study has shown that the absorption, further metabolism, and clearance of oral progesterone are rapid. Within four hours after ingestion maximal plasma concentrations of progesterone had been achieved in all five patients, and peak concentrations of the parent steroid and its three major metabolites occurred simultaneously. Plasma concentrations of progesterone were raised to within the range found in the mid-luteal phase for about six hours, although the values at 24 and 96 hours after the end of treatment were still significantly raised above the baseline. Similar rapid absorption and clearance of progesterone have been reported after rectal and vaginal administration13 and oral ingestion by men.6 Mean (+ SD) concentrations of various steroids in peripheral plasmna offive postmnenopausal womnen before and after oral administration of progesterone 
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The greatest and most prolonged increase in the concentrations of the major metabolites occurred with pregnanediol-3a-glucuronide. The peak mean factorial increase was 20 9, and the mean 24 hours after the end of treatment was 10 3. Concentrations of 17-hydroxyprogesterone were least raised: the peak factorial increase was only 3 7, and within 12 hours after the end of treatment the concentrations had returned to within the pretreatment range.
Unlike the two other metabolites, 20a-dihydroprogesterone is not only biologically effective in its own right14 but is also formed from progesterone in target tissues such as the endometrium."5 Therefore, raised plasma concentrations of this hormone are important in terms of biological activity. In our opinion the plasma concentrations of progesterone and 20x-dihydroprogesterone observed in this study are sufficient to suggest that progesterone given by mouth may affect target tissues. Further studies are needed to determine the end-organ response and therapeutic efficacy. Plasma concentrations that are sustained within the range found in the luteal phase for longer periods may be necessary to achieve the optimal therapeutic response. Logically, administering progesterone either twice daily or in combination with cholesterol pivalate, which increases the bioavailability,6 will produce this effect.
Progestins are prescribed primarily for their anti-oestrogenic effects. Physiologically progesterone is a precursor of oestrogen, and extensive conversion of administered progesterone to oestradiol would be undesirable. The absence of any significant change in oestradiol values during this study is thus reassuring. Clinically, oral progesterone may be of value when synthetic progestogens have caused adverse symptoms that necessitate stopping treatment. These symptoms include acne, breast tenderness, and depression and have been observed during treatment with oral contraceptives3 16 17 and with oestrogen and progestogen preparations used during the menopause (M I Whitehead, P T Townsend, and J McQueen, unpublished observations). No such side effects were reported in this study. In addition, the synthetic progestogen component of the oral contraceptive pill has been linked with more serious hazards such as hypertension,'8 and this effect is possibly mediated through adverse changes in high-density lipoprotein cholesterol.' 9 Naturally occurring progesterone may not alter blood lipids, and as it is stable for two years and cheap it may possibly be usefully combined with oestrogen as a contraceptive and in treating the menopause.
